Interferons
Cytokine group of regulatory molecules
Infergen (interferon acon-1, or consensus interferon)
is an engineered IFN recently approved for the treatment of hepatitis C.
The product’s amino acid sequence reflects the most frequently occurring amino acid residue
in each corresponding position of these native IFNs.
A DNA sequence coding for the product was synthesized and inserted into E. coli.
The recombinant product accumulates intracellularly as inclusion bodies.
Large-scale manufacture entails an initial fermentation step.
After harvest, the E. coli cells are homogenized and the inclusion bodies recovered via centrifugation.
After solubilization and refolding, the interferon is purified to homogeneity by a combination of
chromatographic steps.
The final product is formulated in the presence of a phosphate buffer and sodium chloride.
30mg/ml solution in glass vials displays a shelf-life of 24 months when stored at 2-88C.
When compared on a mass basis, the synthetic interferon displays higher antiviral, antiproliferative and
cytokine-inducing activity than do native type I interferons.